Health
Study assesses cardiovascular and renal outcomes for ertugliflozin in patients with type 2 diabetes – News-Medical.Net
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels
Reviewed by Emily Henderson, B.Sc.Sep 25 2020
A new study led by a cardiologist from Brigham and Women’s Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.
The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) found that the drug had a safety profile similar to that of other SGLT2 inhibitors and did not increase risk of maj…
-
Noosa News18 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
General23 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News15 hours agoHomicide investigation underway after woman found dead in north Brisbane
-
Noosa News15 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense